Day Richard Lj, Harper Ashton J, Woods Rachel M, Davies Owen G, Heaney Liam M
ADM Protexin Ltd, Lopen Head, Somerset, TA13 5JH, UK.
School of Sport, Exercise & Health Sciences, Loughborough University, Loughborough, LE11 3TU, UK.
Future Sci OA. 2019 May 3;5(4):FSO391. doi: 10.4155/fsoa-2019-0004.
In recent years there has been a rapid rise in interest for the application of probiotic supplements to act as mediators in health and disease. This appeal is predominantly due to ever-increasing evidence of the interaction of the microbiota and pathophysiological processes of disease within the human host. This narrative review considers the current landscape of the probiotic industry and its research, and discusses current pitfalls in the lack of translation from laboratory science to clinical application. Future considerations into how industry and academia must adapt probiotic research to maximize success are suggested, including more targeted application of probiotic strains dependent on individual capabilities as well as application of multiple advanced analytical technologies to further understand and accelerate microbiome science.
近年来,将益生菌补充剂用作健康和疾病调节介质的应用受到的关注迅速增加。这种吸引力主要源于越来越多的证据表明微生物群与人类宿主疾病的病理生理过程之间存在相互作用。这篇叙述性综述考虑了益生菌行业及其研究的现状,并讨论了目前在从实验室科学转化为临床应用方面存在的不足。文中提出了对行业和学术界未来如何调整益生菌研究以实现最大成功的思考,包括根据个体能力更有针对性地应用益生菌菌株,以及应用多种先进分析技术来进一步理解和加速微生物组科学。